Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
| Autor: | Lindsey Webster, Sherene Min, Teodora Pene Dumitrescu, Eric Zimmerman, Max Lataillade, Thomas J Greene, Laurie Butcher, Fiona Halliday, Mark Johnson, Samit R Joshi, Theresa T. Pham, Jianfeng Xu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
endocrine system
Cmax Physiology Levonorgestrel Ethinyl Estradiol Pharmacokinetics Medicine Humans Pharmacology (medical) Drug Interactions Adverse effect Progesterone Transaminases Pharmacology business.industry Luteinizing Hormone Contraceptives Oral Combined Tolerability Pharmacodynamics HIV-1 Female Follicle Stimulating Hormone business Luteinizing hormone hormones hormone substitutes and hormone antagonists medicine.drug Hormone |
| Zdroj: | British journal of clinical pharmacology. 88(4) |
| ISSN: | 1365-2125 |
| Popis: | Aims GSK3640254 is a next-generation maturation inhibitor likely to be coadministered with combined oral contraceptives in HIV-positive women. Methods This phase I, open-label, 1-way study assessed pharmacokinetic and pharmacodynamic interactions of GSK3640254 200 mg and ethinyl oestradiol 0.03 mg/levonorgestrel 0.15 mg once daily in healthy female participants who received ethinyl oestradiol/levonorgestrel for 10 days with a moderate-fat meal after which GSK3640254 was added from Days 11 to 21. Primary endpoints were area under the plasma concentration-time curve to the end of the dosing interval (AUC0-t ), maximum observed concentration (Cmax ) and plasma concentration at the end of the dosing interval (Cτ ) for ethinyl oestradiol and levonorgestrel. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations were determined. Adverse events were monitored. Results Among 23 enrolled participants, 17 completed the study. Geometric least squares mean ratios (with vs. without GSK3640254) of AUC0-t , Cmax and Cτ were 0.974, 0.970 and 1.050 for ethinyl oestradiol and 1.069, 1.032 and 1.083 for levonorgestrel, respectively. Three participants had elevated progesterone levels, which occurred before GSK3640254 administration in 2 participants. No participants had elevated follicle-stimulating hormone or luteinizing hormone values. Fourteen participants (61%) reported adverse events. Four participants reported asymptomatic elevated transaminase levels meeting liver-stopping criteria; of these, 3 events occurred before GSK3640254 administration and led to study withdrawal. Conclusion Ethinyl oestradiol/levonorgestrel plus GSK3640254 coadministration did not affect steady-state pharmacokinetics or pharmacodynamics of ethinyl oestradiol and levonorgestrel in healthy female participants. No major tolerability findings were reported. Elevated liver transaminase levels were probably due to ethinyl oestradiol/levonorgestrel. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text